Balyasny Asset Management LLC Prothena Corp Public LTD CO Transaction History

Balyasny Asset Management LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$52.05 - $65.0 $281,070 - $351,000	-5,400 Reduced 82.89%	1,115 $67,000
Q3 2022 Nov 14, 2022	SELL	$25.16 - $60.63 $701,007 - $1.69 Million	-27,862 Reduced 81.05%	6,515 $395,000
Q2 2022 Aug 15, 2022	BUY	$22.73 - $39.98 $781,389 - $1.37 Million	34,377 New	34,377 $933,000
Q1 2020 May 15, 2020	SELL	$7.54 - $15.77 $904,800 - $1.89 Million	-120,000 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$7.48 - $17.01 $897,600 - $2.04 Million	120,000 New	120,000 $1.9 Million
Q3 2018 Nov 14, 2018	SELL	$12.7 - $15.79 $401,459 - $499,137	-31,611 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$10.99 - $44.21 $243,999 - $981,550	22,202 Added 235.97%	31,611 $461,000
Q1 2018 May 15, 2018	BUY	$27.95 - $45.04 $262,981 - $423,781	9,409 New	9,409 $345,000

186

42.8M

162K

102K

Ticker PRTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,922,800
Market Cap $726M
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Balyasny Asset Management LLC with notifications on news.